EMEA-000574-PIP03-23 - paediatric investigation plan
blinatumomab
PIPHuman
Key facts
- Invented name
- Blincyto
- Active Substance
- blinatumomab
- Therapeutic area
- Blood and lymphatic system disorders
- Decision number
- P/0040/2024
- PIP number
- EMEA-000574-PIP03-23
- Pharmaceutical form(s)
- Powder for solution for injection
- Condition(s) / indication(s)
- Treatment of B-lymphoblastic leukaemia/lymphoma
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Amgen Europe B.V.
Tel. +44 (0)1223 420305
E-mail: pipenquiry@amgen.com- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date